Does Dr. MARK DOMANSKI have financial conflicts of interest?

Dr. MARK DOMANSKI (M.D.) has received a total of $3,182 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $3,182 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MARK DOMANSKI?

According to CMS Open Payments data, Dr. MARK DOMANSKI received funding from SMITH+NEPHEW ($972), INTEGRA LIFESCIENCES CORPORATION ($447), and DEPUY SYNTHES SALES ($259).

Does Dr. MARK DOMANSKI receive research grants or speaking fees?

Dr. MARK DOMANSKI has received $3,182 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MARK DOMANSKI

M.D.Real-Time Hydrated

Specialty: Surgery, Plastic and Reconstructive Surgery

Practice Location: FAIRFAX, VA 22031

NPI Number: 1992993885

LIFETIME INDUSTRY VALUE

$3,182

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. DOMANSKI is a verified Surgery, Plastic and Reconstructive Surgery practitioner based in FAIRFAX, VA.

Between 2021 and 2024, Dr. DOMANSKI had an overall industry promotional and research financial footprint of $3,182 as recorded in the federal CMS Open Payments database.

$3,182 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. DOMANSKI's primary funding source is SMITH+NEPHEW, which accounts for $972 (representing 30.6% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

SMITH+NEPHEW

Rank 1

$972

30.6%

INTEGRA LIFESCIENCES CORPORATION

Rank 2

$447

14.1%

DEPUY SYNTHES SALES

Rank 3

$259

8.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.